Basic Utrogestan Information

• INN (International Nonproprietary Name): Dydrogesterone
• Brand Names Available In Australia: Duphaston (packaged as blisters of 20 tablets, 10 mg each) — note that Duphaston is marketed globally and in many European and Asian markets; it is no longer available in the UK (since 2008) and was discontinued in the USA.
• ATC Code: G03DB01
• Forms & Dosages: Tablet, 10 mg strength, supplied in blisters (usually 20 tablets); currently available only as oral tablets with no marketed injectable, cream, or vaginal forms.
• Manufacturers In Australia: Laboratoires Abbott Products (Abbott/AbbVie) is the primary global supplier and MAH; local supply in Australia is typically via Abbott subsidiaries or licensed partners.
• Registration Status In Australia: Registered status should be confirmed with local registries and hospital formularies; internationally Duphaston is registered in most European countries (excluding the UK), Russia and multiple Asian markets.
• OTC / Rx Classification: Prescription-only (Rx) in all countries; not available over-the-counter.

Key Findings From Recent Trials (2022–2025)

Major 2022–2025 Australian & Global Studies

Patients and clinicians want to know: does dydrogesterone actually help in IVF and early miscarriage?

Since 2022, international systematic reviews and several multicentre randomised controlled trials have focused on dydrogesterone for luteal‑phase support in assisted reproduction and for early threatened miscarriage.

Across these studies, dydrogesterone (Duphaston 10 mg tablets) is consistently examined as the oral progestogen option compared with placebo, no luteal support, or alternative progestogens.

The trial evidence up to 2024 shows modest but consistent improvements in clinical pregnancy rates when dydrogesterone is used as luteal support versus placebo or no luteal support.

Meta-analyses emphasise heterogeneity in dosing and regimens across trials, which limits simple summarised effect sizes.

Main Outcomes

Clinical pregnancy rates showed a modest increase in many trials where dydrogesterone was added for luteal-phase support.

Threatened miscarriage studies showed a signal toward reduced pregnancy loss in selected populations, though inclusion criteria differed between trials.

Most trials continued dydrogesterone through early pregnancy in habitual abortion protocols, often up to 20 weeks as noted in product guidance.

Safety Observations (TGA Reports)

Post‑market pharmacovigilance from EU and Asian registers reports mostly mild adverse events such as breast tenderness, nausea and menstrual irregularities.

TGA‑style communications to Australian prescribers emphasise hepatic caution and vigilance for mood changes.

Abbott/AbbVie is the primary MAH and its distribution and monitoring frameworks shape access and safety reporting in Australia.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask: what does dydrogesterone do in plain terms?

Dydrogesterone is a progestogen that mimics the action of your natural progesterone in the uterus.

It helps stabilise the lining of the womb, supports implantation, reduces uterine contractility and helps maintain early pregnancy.

It is taken orally as a tablet, which many patients prefer to vaginal gels or pessaries.

Scientific Breakdown

Pharmacodynamically, dydrogesterone is a selective progesterone receptor agonist that promotes secretory transformation of the endometrium.

It reduces uterine contractility and modulates local immune activation that could otherwise affect an implanted embryo.

Pharmacokinetically, oral 10 mg tablets undergo hepatic metabolism and there are no marketed vaginal or injectable forms.

Metabolites have low androgenic activity compared with some older progestins, which is why dydrogesterone is favoured in some settings.

Clinically, standard doses do not inhibit ovulation, which is useful in infertility care where maintaining a natural cycle is important.

Because the medicine is cleared by the liver, severe liver disease is a contraindication and dose caution is advised.

Product classification is ATC G03DB01 and the only marketed form is 10 mg oral tablets in blister packs supplied by Abbott/AbbVie.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Patients commonly ask whether dydrogesterone is listed on the PBS and what it is approved for in Australia.

Dydrogesterone (Duphaston) is a prescription-only progestogen and its registration and subsidy status can vary by indication.

Product information lists approved uses including secondary amenorrhoea, luteal insufficiency, dysfunctional uterine bleeding, threatened and habitual abortion, and as an adjunct in HRT.

PBS inclusion is variable and depends on the indication and PBAC decisions, so many prescriptions are supplied privately or via hospital formularies when PBS listing is absent or restricted.

Notable Off‑Label Trends In Australian Practice

In Australian fertility clinics, off‑label use of dydrogesterone for luteal‑phase support is common practice when clinicians prefer an oral route over vaginal progesterone.

Recurrent pregnancy loss clinics may individualise dosing beyond standard product regimens, following specialist protocols.

When vaginal routes are not tolerated, clinicians often substitute dydrogesterone for micronised progesterone, balancing route preference and evidence.

Rural prescribers and pharmacists frequently coordinate to secure supplies via mail-order or hospital procurement when local pharmacy stock is limited.

Dosage Strategy

General Dosing

What dose should a patient expect to be prescribed?

Standard adult regimens centre on 10 mg oral tablets with dosing tailored to indication and cycle timing.

Typical general regimens are 10 mg once daily or 10 mg twice daily depending on the condition being treated.

Condition‑Specific Dosing (PBS Recommendations)

For luteal insufficiency or infertility, common dosing is 10 mg daily usually from around day 14 to day 25 of the cycle or continued as directed by the fertility team.

For secondary amenorrhoea or dysfunctional uterine bleeding, a typical regimen is 10 mg twice daily on specified days of the cycle, for example days 11–25.

For threatened abortion, historical trial regimens have used an initial higher loading dose (for example an initial 40 mg divided) followed by 10 mg every 8 hours in some studies, but clinicians should follow local obstetric protocols.

In habitual abortion protocols the product information records use of 10 mg daily continued to at least 20 weeks’ gestation.

When PBS subsidy is not available for a given indication, costs vary between pharmacies and patients may be advised on private script prices.

Safety Protocols

Contraindications (Australian Guidelines)

Patients often ask: who should not take dydrogesterone?

Absolute contraindications include known allergy to dydrogesterone, progestogen‑dependent tumours, active or severe liver disease and undiagnosed vaginal bleeding.

Relative contraindications that require monitoring include a history of depression, thromboembolic disorders, uncontrolled hypertension, renal impairment and diabetes.

Adverse Effects (Post‑Market Pharmacovigilance)

Common side effects reported in post‑market surveillance are usually mild and include breast tenderness, headache, nausea, abdominal discomfort, menstrual irregularities and fatigue.

Rarely, mild oedema is reported and there have been pharmacovigilance signals for mood changes and occasional hepatic enzyme elevations, which is why TGA communications stress hepatic caution and mental health vigilance.

Patients should be counselled to seek immediate care for signs of jaundice, severe mood shifts, or symptoms of thromboembolism such as sudden leg pain or breathlessness.

Baseline history should include VTE risk, liver disease and mood disorders, and pharmacists should arrange timely follow-up after initiation.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Many patients ask whether food or drink affects dydrogesterone absorption.

There are no major documented food interactions for the 10 mg oral tablet form.

Alcohol and high caffeine intake can worsen side effects such as nausea or mood variability, so moderation is sensible when starting therapy.

Patients should store tablets with food advice tailored to tolerance but not for absorption concerns.

Drug Combinations To Avoid (TGA Safety Alerts)

Because dydrogesterone is metabolised hepatically, potent CYP inducers such as rifampicin or certain anticonvulsants may reduce its effectiveness.

Potent CYP inhibitors could theoretically increase dydrogesterone levels, so specialist oversight is advisable when combining such agents.

TGA guidance suggests careful review of concomitant anticoagulant and antiplatelet therapy owing to VTE risk profiles and bleeding considerations.

Pharmacists should use electronic records to flag interactions and perform medicine‑use reviews, particularly in rural settings where access to prescribers can be delayed.

Patient Experience Analysis

Australian Survey Data

Patients commonly ask how dydrogesterone feels compared with vaginal progesterone.

Clinic audits and patient‑reported outcomes from 2020–2024 show high acceptance of oral dydrogesterone for luteal support because of ease of use versus vaginal formulations.

Reported advantages include tolerability and avoidance of local irritation that some patients get with vaginal pessaries or gels.

Concerns raised by patients relate to cost when not PBS‑subsidised and occasional mood disturbances.

Forum And Pharmacy Trends

Online fertility and pregnancy loss forums often discuss efficacy questions, and views typically reflect the advice patients receive from their clinicians.

Community pharmacists at national chains report demand spikes tied to fertility clinic protocols and telehealth prescription growth.

Pharmacists provide practical counselling on side effects, missed-dose action, storage in Australia’s summer heat and options for postal delivery to rural patients.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Availability in community pharmacies varies with supplier allocations and demand from ART centres.

National chains such as Chemist Warehouse, Priceline and TerryWhite may stock Duphaston variably and patients are encouraged to compare prices.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth prescribers and online pharmacies increasingly supply scripts with home delivery, a trend that accelerated after COVID.

In our online pharmacy, utrogestan is available without a prescription, with discreet delivery to Australia in 5-14 days.

This service model is particularly useful for rural patients who find local supply limited.

PBS Vs Private Cost Comparisons

PBS subsidy for dydrogesterone is indication‑specific and variable, so many patients pay privately when PBS listing does not apply.

Out‑of‑pocket cost for a pack of 20 x 10 mg tablets differs between chains and online sellers, and pharmacists often advise comparing prices or considering bulk buying for long courses.

Alternative Options

Comparison Table Of PBS And Non‑PBS Options

Clinicians and patients weigh alternatives by route, side‑effect profile and subsidy status.

Key alternatives include micronised progesterone (oral or vaginal), norethisterone and medroxyprogesterone.

Micronised progesterone is available as soft gels and vaginal pessaries and provides more physiological progesterone levels at the endometrium, but the vaginal route can cause local irritation.

Pros And Cons Checklist

• Dydrogesterone (Duphaston): Oral, well tolerated, preserves ovulation, preferred by patients avoiding vaginal route; limited formulations and hepatic caution apply.
• Micronised Progesterone: Available vaginally and orally, offers high endometrial exposure but can irritate locally and may be less acceptable to some patients.
• Norethisterone/Medroxyprogesterone: Widely available with different metabolic and androgenic profiles to consider when choosing therapy.

Regulatory Status

TGA Approval Framework

In Australia, the Therapeutic Goods Administration governs medicine approvals and scheduling.

Dydrogesterone is classified as prescription-only and prescribers should follow TGA labelling and local hospital formularies.

PBS Subsidy Process

For PBS subsidy, a product must be TGA‑registered and then undergo PBAC evaluation for cost‑effectiveness and listing decisions.

Dydrogesterone’s PBS status varies by indication and clinicians often use hospital procurement or private prescriptions when PBAC listing is not in place.

Consolidated FAQ (Australian Context)

Q1: Is Duphaston on the PBS?

A1: PBS listing is variable and indication‑specific, and many patients pay privately; check the current PBS schedule and compare pharmacy prices.

Q2: Can I take Duphaston if trying to conceive?

A2: Yes; product information supports use for luteal insufficiency and many ART clinics prescribe 10 mg daily as luteal support—discuss with your fertility specialist.

Q3: Any special storage in Australian summers?

A3: Store below 30°C, away from moisture and heat; avoid leaving blister packs in cars or in direct sunlight.

Q4: What if I miss a dose?

A4: Take as soon as remembered unless it is almost time for the next dose; do not double up and contact your pharmacist or GP if unsure.

Q5: Where can I get it in rural areas?

A5: Local pharmacies can order stock or arrange postal supply; national chains and telehealth suppliers commonly assist with home delivery.

Visual Guide (Infographic Prompts)

Infographic 1: “Dydrogesterone At A Glance” showing INN, brand Duphaston, ATC G03DB01, 10 mg tablet image, manufacturer Abbott/AbbVie and common indications.

Infographic 2: “Cost & Access Map” with PBS vs private cost comparison bars and typical price ranges at Chemist Warehouse, Priceline and TerryWhite plus telehealth icons.

Infographic 3: “Supply Chain & Rural Access” flowchart from MAH to wholesaler to chain/hospital/rural pharmacy to patient, highlighting postal delivery and heat‑avoidance storage tips.

Infographic 4: “Quick Counselling Card” with contraindications, common side effects, missed dose advice and emergency signs for VTE or hepatic events.

Storage & Transport

Household Storage Under Australian Climate

Store dydrogesterone below 30°C and keep tablets in their original blister packaging away from moisture and heat.

Avoid bathroom cabinets due to humidity and do not leave blister packs in cars or in direct sunlight during hot weather.

Advise patients to keep tablets in a cool, dry cupboard and to replace stock if prolonged heat exposure is suspected.

Cold‑Chain Logistics For Pharmacies

As a solid oral tablet, dydrogesterone does not require refrigerated or cold‑chain transport but should not be stored above 30°C for prolonged periods.

Wholesalers and pharmacies should avoid extended transit in heat and rural pharmacies should use tracked standard‑temperature couriers with prompt delivery.

Pharmacists can provide a heat‑safe storage leaflet and arrange replacements where heat exposure may have occurred.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

When handing out dydrogesterone, pharmacists should use patient‑centred counselling, confirming the indication and reviewing contraindications.

Discuss VTE risk, liver disease history and any mood disorder, and check concomitant medicines for CYP inducers or anticoagulant therapy.

Set expectations about common side effects such as breast tenderness, nausea and spotting and give clear missed‑dose advice.

Document counselling in the patient medication record and arrange follow‑up calls if the patient lives in a rural area.

National Health Authority Recommendations

Follow TGA labelling, local hospital formularies and pharmacovigilance reporting pathways.

Escalate and report any suspected serious adverse events to the TGA and collaborate with GPs and obstetricians for complex cases.

Delivery Across Australia

Final Notes For Patients

Utrogestan is a commonly requested search term when patients compare oral progestogens, but note that utrogestan is a brand name more commonly used for micronised progesterone formulations rather than dydrogesterone.

Dydrogesterone (Duphaston 10 mg tablets) is favoured for its lack of androgenic, estrogenic or glucocorticoid effects and for preserving ovulation at standard doses.

If you are using this medicine for fertility or miscarriage prevention, follow your specialist’s protocol for dosing and duration and keep regular contact with your pharmacist.

Report any worrying symptoms such as jaundice, severe mood changes or signs of thrombosis promptly and keep a copy of your prescription for hospital or interstate care coordination.